Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors
出版年份 2023 全文链接
标题
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors
作者
关键词
-
出版物
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-01-28
DOI
10.1007/s00262-023-03381-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Topographic mapping of the glioblastoma proteome reveals a triple-axis model of intra-tumoral heterogeneity
- (2022) K. H. Brian Lam et al. Nature Communications
- mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers
- (2022) Lei Cheng et al. Journal of Translational Medicine
- Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment
- (2022) Anqi Lin et al. Journal of Immunology Research
- KRAS ‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
- (2022) Chengming Liu et al. Cancer Communications
- Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial
- (2021) David A. Reardon et al. CANCER
- Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of SPATS2L in Patients With Glioma
- (2021) Haiwei Wang et al. Frontiers in Oncology
- Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
- (2021) Manmeet Singh Ahluwalia et al. JOURNAL OF CLINICAL ONCOLOGY
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
- (2021) David N Louis et al. NEURO-ONCOLOGY
- Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment
- (2021) Simran S. Kapoor et al. Biomedicines
- Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors
- (2020) Joseph Song et al. NEURO-ONCOLOGY
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
- (2020) David A. Reardon et al. JAMA Oncology
- Microglia promote glioblastoma via mTOR‐mediated immunosuppression of the tumour microenvironment
- (2020) Anaelle A Dumas et al. EMBO JOURNAL
- Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
- (2020) Lakshmi Nayak et al. CLINICAL CANCER RESEARCH
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
- (2019) Junfei Zhao et al. NATURE MEDICINE
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
- (2019) Timothy F. Cloughesy et al. NATURE MEDICINE
- Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
- (2019) Antonio Santaniello et al. Cancers
- Retrospective study of nivolumab for patients with recurrent high grade gliomas
- (2018) Megan Mantica et al. JOURNAL OF NEURO-ONCOLOGY
- Prognostic significance of epidermal growth factor receptor expression in glioma patients
- (2018) Junhong Li et al. OncoTargets and Therapy
- Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
- (2018) Carl Morrison et al. Journal for ImmunoTherapy of Cancer
- PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma
- (2018) Sylvia C. Kurz et al. NEUROLOGY
- Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series
- (2017) Marc C. Chamberlain et al. JOURNAL OF NEURO-ONCOLOGY
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
- (2017) Antonio Omuro et al. NEURO-ONCOLOGY
- Lomustine and Bevacizumab in Progressive Glioblastoma
- (2017) Wolfgang Wick et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
- (2017) Zhong-Yi Dong et al. OncoImmunology
- Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
- (2017) Samantha N. Reiss et al. Journal for ImmunoTherapy of Cancer
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
- (2016) Eric Bouffet et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
- (2010) H.-W. Lo CURRENT CANCER DRUG TARGETS
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now